StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Acetyldigitoxin

HCID 5284512
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1111-39-3
Standard-SMILES
CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O
InChIKey
HPMZBILYSWLILX-UMDUKNJSSA-N
Summenformel
C43H66O14
Durchschnittliche Molmasse
807 g/mol
Monoisotopische Masse
806,44525677

Überblick

3'''-O-acetyldigitoxin is a cardenolide glycoside compound consisting of digitoxin having an acetyl substituent at the 3-position on the D-ribo-hexopyranosyl residue at the non-reducing end. It has a role as an enzyme inhibitor, an anti-arrhythmia drug and a cardiotonic drug. It is functionally related to a digitoxin.

Namen und Bezeichner

Bevorzugter Name
Acetyldigitoxin
IUPAC
[(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
Lokaler Name
Acetyldigitoxin
Englischer Name
ACETYLDIGITOXIN
Summenformel
C43H66O14
Molmasse
806.98

Namen und Synonyme

acetyldigitoxin1111-39-3alpha-AcetyldigitoxinDesglucolanatoside AAcylanidAcetildigitoxinaAcetyldiginatinDigitoxin 3'''-acetatealpha-MonoacetyldigitoxinAcetyldigitoxinumAcetyl-digitoxin-alphaacetyldigitoxine
Weitere Namen anzeigen
adicina-FormAcedigal3'''-Acetyldigitoxin
0ZV4Q4L2FU[(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetateCHEBI:53773DTXSID6022551acetildigitossina((2R,3R,4S,6S)-3-hydroxy-6-((2R,3S,4S,6S)-4-hydroxy-6-((2R,3S,4S,6R)-4-hydroxy-6-(((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta(a)phenanthren-3-yl)oxy)-2-methyloxan-3-yl)oxy-2-methyloxan-3-yl)oxy-2-methyloxan-4-yl) acetate(2R,3R,4S,6S)-3-hydroxy-6-(((2R,3S,4S,6S)-4-hydroxy-6-(((2R,3S,4S,6R)-4-hydroxy-6-(((1S,2S,5S,7R,10R,11S,14R,15R)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo(8.7.0.0^(2,7).0^(11,15))heptadecan-5-yl)oxy)-2-methyloxan-3-yl)oxy)-2-methyloxan-3-yl)oxy)-2-methyloxan-4-yl acetate(2R,3R,4S,6S)-3-hydroxy-6-{[(2R,3S,4S,6S)-4-hydroxy-6-{[(2R,3S,4S,6R)-4-hydroxy-6-{[(1S,2S,5S,7R,10R,11S,14R,15R)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-4-yl acetate

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,8
Polarare Oberfläche (TPSA)
189 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
14
Frei drehbare Bindungen
9
Schwere Atome
57
Formalladung
0
Komplexität
1.520

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 Einträge

3.7

1.97

Solubility1.23e-02 g/L
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt
217 · 217-221°
Siedepunkt
673.84 °C · 673.84°C (rough estimate)
Dichte
1.1009 · 1.1009 (rough estimate)
Brechungsindex
1.613 · 1.6130 (estimate)
storage temp.
-20 °C · Store at -20°C
Löslichkeit
Chloroform: Slightly Soluble; DMSO: Slightly Soluble; Methanol: Slightly Soluble

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Sicherheitsdaten

ridadr
3249
hazard_class
6.1(a)
packing_group
II

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 Eintrag

The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na<sup>+</sup>/K<sup>+</sup> ATPase pump.

Mechanism of Action · 1 Eintrag

Acetyldigitoxin binds to a site on the extracellular aspect of the &alpha;-subunit of the Na<sup>+</sup>/K<sup>+</sup> ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na<sup>+</sup>/K<sup>+</sup> pump leads to increased Na<sup>+</sup> levels, which in turn slows down the extrusion of Ca<sup>2+</sup> via the Na<sup>+</sup>/Ca<sup>2+</sup> exchange pump. Increased amounts of Ca<sup>2+</sup> are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias.

MeSH Pharmacological Classification · 3 Einträge

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
1111-39-3、25395-32-8
PubChem CID
5284512
ChEMBL
CHEMBL3545057
ChEBI
CHEBI:53773
UNII
0ZV4Q4L2FU
EC Number
214-178-4、246-942-8
Nikkaji
J217.225I
Aggregatzustand
A solid
Stabilität
Hygroscopic

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

Absorption, Distribution and ExcretionBioavailability is 60 to 80% following oral administration.
Cellular LocationsExtracellular